PolyPeptide Group AG (SWX:PPGN)
43.95
0.00 (0.00%)
Aug 21, 2026, 5:31 PM CET
PolyPeptide Group AG Revenue
PolyPeptide Group AG had revenue of 246.90M EUR in the half year ending June 30, 2026, with 81.77% growth. This brings the company's revenue in the last twelve months to 471.25M, up 27.18% year-over-year. In the year 2025, PolyPeptide Group AG had annual revenue of 391.95M with 15.70% growth.
Revenue (ttm)
471.25M EUR
Revenue Growth
+27.18%
P/S Ratio
3.43
Revenue / Employee
322.77K EUR
Employees
1,460
Market Cap
1.45B CHF
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 391.95M | 53.18M | 15.70% |
| Dec 31, 2024 | 338.77M | 13.92M | 4.28% |
| Dec 31, 2023 | 324.85M | 41.39M | 14.60% |
| Dec 31, 2022 | 283.46M | -2.75M | -0.96% |
| Dec 31, 2021 | 286.22M | 61.41M | 27.31% |
| Dec 31, 2020 | 224.81M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Roche Holding AG | 62.96B |
| Novartis AG | 45.81B |
| Lonza Group AG | 6.87B |
| Galderma Group AG | 4.79B |
| Aevis Victoria | 1.04B |
| Tecan Group AG | 870.53M |
| Medacta Group | 636.66M |
| SKAN Group AG | 363.25M |
PolyPeptide Group AG News
- 10 days ago - PolyPeptide Group AG Earnings Call Transcript: H1 2026 - Transcripts
- 10 days ago - PolyPeptide Group AG Earnings release: H1 2026 - Filings
- 10 days ago - PolyPeptide Group AG Quarterly report: H1 2026 - Filings
- 10 days ago - PolyPeptide Group AG Slides: H1 2026 - Filings
- 4 weeks ago - Samsung Biologics (005940) Proposes $1.8 Billion Acquisition of Polypeptide Group - GuruFocus
- 4 weeks ago - PolyPeptide Receives CHF 1.46 Bln Samsung Offer, Posts Strong H1 Prelim. Result, Raises Guidance - Nasdaq
- 4 weeks ago - Samsung Biologics to Acquire PolyPeptide Group for $1.8 Billion - GuruFocus
- 4 weeks ago - Samsung Biologics To Enter Peptide CDMO Market With CHF 1.46 Bln PolyPeptide Acquisition; Stock Down - Nasdaq